{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:56:55Z","timestamp":1769259415080,"version":"3.49.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microvascular Research"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.mvr.2025.104896","type":"journal-article","created":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T15:13:31Z","timestamp":1765120411000},"page":"104896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Vascular diameter and responsiveness to soluble guanylate cyclase modulators: A systematic review of preclinical and clinical evidence"],"prefix":"10.1016","volume":"164","author":[{"given":"M.S.","family":"Josef","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.mvr.2025.104896_bb0005","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/DCR.0b013e31819ed3bc","article-title":"Preoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patients","volume":"52","author":"Alabi","year":"2009","journal-title":"Dis. Colon Rectum"},{"issue":"5","key":"10.1016\/j.mvr.2025.104896_bb0010","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/jsm.12095","article-title":"Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure","volume":"10","author":"Albersen","year":"2013","journal-title":"J. Sex. Med."},{"issue":"18","key":"10.1016\/j.mvr.2025.104896_bb0015","doi-asserted-by":"crossref","first-page":"29613","DOI":"10.18632\/oncotarget.16769","article-title":"Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension","volume":"8","author":"Amirjanians","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.mvr.2025.104896_bb0020","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1054\/bjoc.2001.2193","article-title":"Increased endothelin 1 in colorectal cancer and reduction of tumor growth by ET(A) receptor antagonism","volume":"85","author":"Asham","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.mvr.2025.104896_bb0025","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.01101.2009","article-title":"Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide","volume":"299","author":"Badejo","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.mvr.2025.104896_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.864010","article-title":"Cinaciguat (BAY-582667) modifies cardiopulmonary and systemic circulation in chronically hypoxic and pulmonary hypertensive neonatal lambs in the Alto Andino","volume":"13","author":"Be\u00f1aldo","year":"2022","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.mvr.2025.104896_bb0035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1527-3466.2007.00003.x","article-title":"Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease","volume":"25","author":"Boerrigter","year":"2007","journal-title":"Cardiovasc. Drug Rev."},{"issue":"5","key":"10.1016\/j.mvr.2025.104896_bb0040","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"LEPHT study group. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study","volume":"128","author":"Bonderman","year":"2013","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.mvr.2025.104896_bb0045","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1172\/JCI60119","article-title":"Genetic modifiers of hypertension in soluble guanylate cyclase \u03b11-deficient mice","volume":"122","author":"Buys","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mvr.2025.104896_bb0050","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cbpa.2019.05.006","article-title":"Regulation of glyceraldehyde-3-phosphate dehydrogenase by hypoxia inducible factor 1 in the white shrimp Litopenaeus vannamei during hypoxia and reoxygenation","volume":"235","author":"Camacho-Jim\u00e9nez","year":"2019","journal-title":"Comp. Biochem. Physiol. A Mol. Integr. Physiol."},{"key":"10.1016\/j.mvr.2025.104896_bb0055","doi-asserted-by":"crossref","first-page":"1480186","DOI":"10.3389\/fphar.2024.1480186","article-title":"Comparison of sGC activator and sGC stimulator in 5\/6 nephrectomized rats on high-salt diet","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.mvr.2025.104896_bb0060","first-page":"L318","article-title":"Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus","volume":"297","author":"Chester","year":"2009","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"issue":"3","key":"10.1016\/j.mvr.2025.104896_bb0065","first-page":"128","article-title":"Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress","volume":"5","author":"Costell","year":"2012","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.mvr.2025.104896_bb0070","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/SHK.0b013e3181e14f1d","article-title":"Neonatal asphyxia induces the nitration of cardiac myosin light chain 2 that is associated with cardiac systolic dysfunction","volume":"34","author":"Doroszko","year":"2010","journal-title":"Shock"},{"issue":"1","key":"10.1016\/j.mvr.2025.104896_bb0075","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/eurheartj\/ehs196","article-title":"Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure","volume":"34","author":"Erdmann","year":"2013","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.mvr.2025.104896_bb0080","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/ndt\/gfae261","article-title":"The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial","volume":"40","author":"Gansevoort","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"issue":"6","key":"10.1016\/j.mvr.2025.104896_bb0085","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/ndt\/gfae261","article-title":"The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial","volume":"40","author":"Gansevoort","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"issue":"9","key":"10.1016\/j.mvr.2025.104896_bb0090","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/eurjhf\/hfs093","article-title":"Effect of cinaciguat on clinical status and safety in acute decompensated heart failure: results from the randomized, placebo-controlled COMPOSE program","volume":"14","author":"Gheorghiade","year":"2012","journal-title":"Eur. J. Heart Fail."},{"issue":"21","key":"10.1016\/j.mvr.2025.104896_bb0095","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels and clinical outcomes in patients with worsening chronic heart failure","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.mvr.2025.104896_bb0100","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.mvr.2025.104896_bb0105","doi-asserted-by":"crossref","first-page":"H297","DOI":"10.1152\/ajpheart.00079.2015","article-title":"Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes","volume":"309","author":"Goulopoulou","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"5","key":"10.1016\/j.mvr.2025.104896_bb0110","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cpdd.627","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of praliciguat, a soluble guanylate cyclase stimulator, in healthy participants and participants with type 2 diabetes and hypertension","volume":"8","author":"Hanrahan","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"4","key":"10.1016\/j.mvr.2025.104896_bb0115","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00125-019-05062-x","article-title":"Effects of praliciguat, a soluble guanylate cyclase stimulator, on metabolic and hemodynamic measures in people with type 2 diabetes and hypertension: a randomized trial","volume":"63","author":"Hanrahan","year":"2020","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.mvr.2025.104896_bb0120","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.0000000000000418","article-title":"Effect of avenciguat on albuminuria in patients with CKD: two randomized placebo-controlled trials","volume":"35","author":"Heerspink","year":"2024","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.mvr.2025.104896_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2011.02.011","article-title":"Up-regulation of glyceraldehyde-3-phosphate dehydrogenase gene expression by HIF-1 activity depending on Sp1 in hypoxic breast cancer cells","volume":"509","author":"Higashimura","year":"2011","journal-title":"Arch. Biochem. Biophys."},{"issue":"5","key":"10.1016\/j.mvr.2025.104896_bb0130","doi-asserted-by":"crossref","first-page":"2401110","DOI":"10.1183\/13993003.01110-2024","article-title":"MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study","volume":"64","author":"Hoeper","year":"2024","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.mvr.2025.104896_bb0135","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1097\/HJH.0000000000004009","article-title":"The treatment with soluble guanylate cyclase stimulator BAY41-8543 prevents malignant hypertension and associated organ damage","volume":"43","author":"H\u00fcttl","year":"2025","journal-title":"J. Hypertens."},{"issue":"8","key":"10.1016\/j.mvr.2025.104896_bb0140","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1093\/rheumatology\/keaf109","article-title":"Avenciguat: a novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN-1 signalling and fibrosis","volume":"64","author":"Kaufman","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.mvr.2025.104896_bb0145","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1074248409333266","article-title":"The cyclic GMP modulators YC-1 and zaprinast reduce vessel remodeling through antiproliferative and proapoptotic effects","volume":"14","author":"Keswani","year":"2009","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.mvr.2025.104896_bb0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/23971983241291923","article-title":"A phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: study design and rationale of the VITALISScE\u2122 study","volume":"10","author":"Khanna","year":"2024","journal-title":"J. Scleroderma Relat. Disord."},{"issue":"17","key":"10.1016\/j.mvr.2025.104896_bb0155","doi-asserted-by":"crossref","first-page":"13226","DOI":"10.3390\/ijms241713226","article-title":"The sGC activator runcaciguat has kidney protective effects and prevents a decline of kidney function in ZSF1 rats","volume":"24","author":"Kraehling","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.mvr.2025.104896_bb0160","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/01.CIR.92.3.518","article-title":"Longitudinal gradients for endothelium-dependent and -independent vascular responses in coronary microcirculation","volume":"92","author":"Kuo","year":"1995","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.mvr.2025.104896_bb0165","article-title":"The soluble guanylate cyclase stimulator riociguat improves pulmonary hemodynamics and vascular remodeling in the SU5416\/hypoxia rat model of severe pulmonary arterial hypertension","volume":"7","author":"Lang","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.mvr.2025.104896_bb0170","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.kint.2024.10.025","article-title":"Activating soluble guanylyl cyclase attenuates ischemic kidney damage","volume":"107","author":"Lichtenberger","year":"2025","journal-title":"Kidney Int."},{"key":"10.1016\/j.mvr.2025.104896_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2025.107515","article-title":"Vascular diameter determines sensitivity to soluble guanylate cyclase activation in human mesenteric and renal arteries","volume":"160","author":"Lubomirov","year":"2025","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.mvr.2025.104896_bb0180","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12933-015-0309-x","article-title":"The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus","volume":"14","author":"M\u00e1ty\u00e1s","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"issue":"7","key":"10.1016\/j.mvr.2025.104896_bb0185","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.healun.2019.03.004","article-title":"Differential effects of ischemia\/reperfusion on endothelial function and contractility in donation after circulatory death","volume":"38","author":"M\u00e9ndez-Carmona","year":"2019","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.mvr.2025.104896_bb0190","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ahj.2021.07.003","article-title":"Impact of oral soluble guanylate cyclase stimulators in heart failure: a systematic review and meta-analysis of randomized controlled trials","volume":"241","author":"Moghaddam","year":"2021","journal-title":"Am. Heart J."},{"issue":"4","key":"10.1016\/j.mvr.2025.104896_bb0195","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/sj.bjp.0700982","article-title":"Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators","volume":"120","author":"M\u00fclsch","year":"1997","journal-title":"Br. J. Pharmacol."},{"issue":"14","key":"10.1016\/j.mvr.2025.104896_bb0200","first-page":"949","article-title":"Vascular redox signaling, oxidative stress and endothelial dysfunction in metabolic and cardiovascular disease","volume":"38","author":"M\u00fcnzel","year":"2017","journal-title":"Eur. Heart J."},{"issue":"17","key":"10.1016\/j.mvr.2025.104896_bb0205","article-title":"The effect of Riociguat on cardiovascular function and efficiency in healthy, juvenile pigs","volume":"8","author":"Naesheim","year":"2020","journal-title":"Phys. Rep."},{"issue":"3","key":"10.1016\/j.mvr.2025.104896_bb0210","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1073\/pnas.0237367100","article-title":"Beneficial effects of antioxidants and L-arginine on oxidation-sensitive gene expression and endothelial NO synthase activity at sites of disturbed shear stress","volume":"100","author":"de Nigris","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.mvr.2025.104896_bb0215","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1152\/physrev.00005.2022","article-title":"The superoxide radical switch in the biology of nitric oxide and peroxynitrite","volume":"102","author":"Piacenza","year":"2022","journal-title":"Physiol. Rev."},{"issue":"6","key":"10.1016\/j.mvr.2025.104896_bb0220","doi-asserted-by":"crossref","first-page":"H1347","DOI":"10.1152\/ajpheart.00544.2011","article-title":"Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia\/reperfusion injury: role of hydrogen sulfide","volume":"302","author":"Salloum","year":"2012","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"3","key":"10.1016\/j.mvr.2025.104896_bb0225","article-title":"Discovery of TY-55002: a short-acting soluble guanylate cyclase activator with reduced risk of hypotension","volume":"7","author":"Sawabe","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"issue":"1","key":"10.1016\/j.mvr.2025.104896_bb0230","doi-asserted-by":"crossref","first-page":"9372","DOI":"10.1038\/s41598-018-27656-y","article-title":"The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats","volume":"8","author":"Schwabl","year":"2018","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.mvr.2025.104896_bb0235","doi-asserted-by":"crossref","first-page":"487","DOI":"10.4103\/2045-8932.93548","article-title":"Hypoxia modulates the expression of leucine zipper-positive MYPT1 and its interaction with protein kinase G and rho kinases in pulmonary arterial smooth muscle cells","volume":"1","author":"Singh","year":"2011","journal-title":"Pulm. Circ."},{"issue":"5","key":"10.1016\/j.mvr.2025.104896_bb0240","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.transproceed.2007.02.079","article-title":"Guanylate cyclase activators influence reactivity of human mesenteric superior arteries retrieved and preserved in the same conditions as transplanted kidneys","volume":"39","author":"Slupski","year":"2007","journal-title":"Transplant. Proc."},{"issue":"5","key":"10.1016\/j.mvr.2025.104896_bb0245","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/sj.bjp.0704778","article-title":"NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle","volume":"136","author":"Stasch","year":"2002","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.mvr.2025.104896_bb0250","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.bjp.0704484","article-title":"Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies","volume":"135","author":"Stasch","year":"2002","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.mvr.2025.104896_bb0255","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1172\/JCI28371","article-title":"Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels","volume":"116","author":"Stasch","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.mvr.2025.104896_bb0260","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1111\/bph.15586","article-title":"Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney","volume":"179","author":"Stehle","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.mvr.2025.104896_bb0265","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1159\/000371491","article-title":"Effects of peroxynitrite on relaxation through the NO\/sGC\/cGMP pathway in isolated rat iliac arteries","volume":"51","author":"Tawa","year":"2014","journal-title":"J. Vasc. Res."},{"issue":"3","key":"10.1016\/j.mvr.2025.104896_bb0270","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000498896","article-title":"Chronological change of vascular reactivity to cGMP generators in the balloon-injured rat carotid artery","volume":"56","author":"Tawa","year":"2019","journal-title":"J. Vasc. Res."},{"issue":"3","key":"10.1016\/j.mvr.2025.104896_bb0275","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1124\/jpet.123.001918","article-title":"Efficacy of BAY 60-2770, a soluble guanylate cyclase activator, for coronary spasm in animal models","volume":"390","author":"Tawa","year":"2024","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"17","key":"10.1016\/j.mvr.2025.104896_bb0280","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1111\/bph.15492","article-title":"Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease","volume":"178","author":"Tchernychev","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.mvr.2025.104896_bb0285","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/01.HYP.0000199914.36936.1b","article-title":"Vasorelaxing effect of BAY 41-2272 in rat basilar artery: involvement of cGMP-dependent and independent mechanisms","volume":"47","author":"Teixeira","year":"2006","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.mvr.2025.104896_bb0290","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1124\/jpet.105.095752","volume":"317","author":"Teixeira","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.mvr.2025.104896_bb0295","doi-asserted-by":"crossref","first-page":"8482","DOI":"10.1038\/ncomms9482","article-title":"Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice","volume":"6","author":"Thoonen","year":"2015","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.mvr.2025.104896_bb0300","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/jpet.117.247429","article-title":"Pharmacological characterization of IW-1973, a novel soluble guanylate cyclase stimulator","volume":"365","author":"Tobin","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"15","key":"10.1016\/j.mvr.2025.104896_bb0305","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1001\/jama.2020.16641","article-title":"Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: the CAPACITY-HFpEF randomized clinical trial","volume":"324","author":"Udelson","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mvr.2025.104896_bb0310","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/apha.12646","article-title":"Endothelial dysfunction and vascular disease - a 30th anniversary update","volume":"219","author":"Vanhoutte","year":"2017","journal-title":"Acta Physiol (Oxford)"},{"issue":"3","key":"10.1016\/j.mvr.2025.104896_bb0315","first-page":"C695","article-title":"Regulation of VEGF-induced endothelial cell migration by mitochondrial reactive oxygen species","volume":"301","author":"Wang","year":"2011","journal-title":"Am. J. Phys. Cell Phys."},{"issue":"4","key":"10.1016\/j.mvr.2025.104896_bb0320","first-page":"L658","article-title":"The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice","volume":"297","author":"Weissmann","year":"2009","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"issue":"4","key":"10.1016\/j.mvr.2025.104896_bb0325","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96006","article-title":"Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction","volume":"3","author":"Wilck","year":"2018","journal-title":"JCI Insight"},{"issue":"13","key":"10.1016\/j.mvr.2025.104896_bb0330","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.3390\/ijms23137016","article-title":"Nitric oxide signalling in descending vasa recta after hypoxia\/re-oxygenation","volume":"23","author":"Xu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"41","key":"10.1016\/j.mvr.2025.104896_bb0335","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012709","article-title":"The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis","volume":"97","author":"Zheng","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.mvr.2025.104896_bb0340","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1186\/s12885-021-08430-2","article-title":"Nitric oxide in occurrence, progress and therapy of lung cancer: a systemic review and meta-analysis","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.mvr.2025.104896_bb0345","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3389\/fphar.2020.00419","article-title":"Olinciguat, an oral sGC stimulator, exhibits diverse pharmacology across preclinical models of cardiovascular, metabolic, renal, and inflammatory disease","volume":"11","author":"Zimmer","year":"2020","journal-title":"Front. Pharmacol."}],"container-title":["Microvascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026286225001153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026286225001153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:23:16Z","timestamp":1769145796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026286225001153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":69,"alternative-id":["S0026286225001153"],"URL":"https:\/\/doi.org\/10.1016\/j.mvr.2025.104896","relation":{},"ISSN":["0026-2862"],"issn-type":[{"value":"0026-2862","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vascular diameter and responsiveness to soluble guanylate cyclase modulators: A systematic review of preclinical and clinical evidence","name":"articletitle","label":"Article Title"},{"value":"Microvascular Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mvr.2025.104896","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104896"}}